Cargando…

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer

Endocrine therapy is a recognised option in the treatment of chemo-resistant ovarian cancer. We conducted a nonrandomised phase II evaluation of combination endocrine therapy with tamoxifen and goserelin in patients with advanced ovarian cancer that had recurred following chemotherapy. In total, 26...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hasan, J, Ton, N, Mullamitha, S, Clamp, A, McNeilly, A, Marshall, E, Jayson, G C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361624/ https://www.ncbi.nlm.nih.gov/pubmed/16222310 http://dx.doi.org/10.1038/sj.bjc.6602752

Ejemplares similares

A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
por: Lind, M. J., et al.
Publicado: (1992)

A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
por: Clamp, A R, et al.
Publicado: (2003)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial
por: NISHIMURA, REIKI, et al.
Publicado: (2013)

Goserelin Ovarian Ablation Failure in Premenopausal Women With Breast Cancer
por: Gupta, Aanchal, et al.
Publicado: (2021)

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer
por: De Placido, S, et al.
Publicado: (2005)

Thrombosis in ovarian cancer: a case control study
por: Metcalf, R L, et al.
Publicado: (2014)

Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.
por: Philip, P. A., et al.
Publicado: (1993)

Reinduction of Hormone Sensitivity to Goserelin following Chemotherapy with Vinorelbine in Castration-Resistant Prostate Cancer
por: Grenader, Tal, et al.
Publicado: (2010)

Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial
por: Yang, H, et al.
Publicado: (2013)

Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology.
por: Buzzoni, R., et al.
Publicado: (1995)

Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer
por: Wang, Jiayu, et al.
Publicado: (2015)

Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study
por: Heo, Jung-Yoon, et al.
Publicado: (2017)

Profiling Heparan Sulfate Proteoglycans in Ovarian Carcinoma
por: Clamp, Andrew R., et al.
Publicado: (2005)

Antiangiogenic drugs in ovarian cancer
por: Kumaran, G C, et al.
Publicado: (2009)

Inhibin removes the inhibitory effects of activin on steroid enzyme expression and androgen production by normal ovarian thecal cells
por: Young, J M, et al.
Publicado: (2012)

Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
por: Lindemann, Kristina, et al.
Publicado: (2017)

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer
por: Clamp, A R, et al.
Publicado: (2006)

Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway
por: Zhang, Ning, et al.
Publicado: (2018)

Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial
por: Li, Jian-wei, et al.
Publicado: (2018)

Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment
por: Campbell, Aideen M, et al.
Publicado: (2018)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover
por: Wilson, Caroline, et al.
Publicado: (2016)

Update on the management of prostate cancer with goserelin acetate: patient perspectives
por: Wilson, Shandra
Publicado: (2009)

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.
por: Dixon, A. R., et al.
Publicado: (1990)

Does clinical trial participation improve outcomes in patients with ovarian cancer?
por: Khoja, L, et al.
Publicado: (2016)

Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced Amenorrhea
por: Zhou, Juan, et al.
Publicado: (2015)

Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin
por: Abdel Azim, Hamdy, et al.
Publicado: (2018)

Unsuspected Skin Metastasis of Adenocarcinoma of the Prostate in a Patient on Goserelin (Zoladex)
por: Mbaeri, Timothy Uzoma, et al.
Publicado: (2018)

Goserelin-Induced Chemical Burn: A Case Report and Review of the Literature
por: Mahadevan, Aditya, et al.
Publicado: (2023)

Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer
por: Steffensen, Karina Dahl, et al.
Publicado: (2011)

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
por: Munster, P N, et al.
Publicado: (2011)

Tamoxifen and Ovarian Function
por: Berliere, Martine, et al.
Publicado: (2013)

Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram
por: Lash, T L, et al.
Publicado: (2008)

Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
por: McMeekin, S, et al.
Publicado: (2012)

Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection
por: Onda, T, et al.
Publicado: (2005)

Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
por: Jonat, W
Publicado: (2002)

Goserelin (Zoladex™) – its role in early breast cancer in pre- and perimenopausal women
por: Jonat, W
Publicado: (2001)

Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
por: Hackshaw, Allan, et al.
Publicado: (2009)

Primary Mediastinal Choriocarcinoma in an Elderly Patient with Concurrent Goserelin-Treated Prostate Adenocarcinoma
por: Røge, Rasmus, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jn9btn9oo9gs41c13k6d20vt5k